

TSPEAR Rabbit pAb

Catalog # AP96841

Product Information

Application	WB, IHC-P, IHC-F, IF, E
Primary Accession	Q8WU66
Other Accession	Q8WU66
Host	Rabbit
Clonality	Polyclonal
Calculated MW	74924
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human TSPEAR/C21orf9
Epitope Specificity	581-669/669
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	This gene encodes a protein that contains a N-terminal thrombospondin-type laminin G domain and several tandem arranged epilepsy-associated repeats (EARs). A mutation in this gene is the cause of autosomal recessive deafness-98. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Dec 2012]

Additional Information

Gene ID	54084
Other Names	TSEAR_HUMAN; Thrombospondin-type laminin G domain and EAR repeat-containing protein; SP-EAR; C21orf29;
Dilution	WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	TSPEAR
Synonyms	C21orf29
Function	Plays a critical role in tooth and hair follicle morphogenesis through

regulation of the Notch signaling pathway (PubMed:[27736875](#)). May play a role in development or function of the auditory system (PubMed:[22678063](#)).

Cellular Location

Secreted {ECO:0000250|UniProtKB:J3S6Y1}. Cell surface {ECO:0000250|UniProtKB:J3S6Y1}. Cell projection, stereocilium {ECO:0000250|UniProtKB:J3S6Y1}. Note=Secreted protein which may bind to the cell surface via a membrane receptor {ECO:0000250|UniProtKB:J3S6Y1}

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.